EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective

Kai-Michael Beeh iD, Jing Claussen iD, Dhvani Shah, Alan Martin iD, Robyn Kendall iD, Priyadarsini Dasari, Afisi S Ismaila iD, Stephen G Noorduyn

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s492524 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Kai-Michael Beeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Insaf Respiratory Research Institute, Taunusstein, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Chlorobenzenes, Bronchodilator Agents, Benzyl Alcohols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The INTREPID trial showed that once-daily single-inhaler triple therapy (SITT) using fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) offers clinical benefits versus non-ELLIPTA multiple-inhaler triple therapy (MITT) for the management of chronic obstructive pulmonary disease (COPD) in real-world clinical practice. This analysis evaluated the cost-effectiveness of SITT with FF/UMEC/VI versus non-ELLIPTA MITT for treating symptomatic COPD from a German healthcare perspective. Patients and Methods: Data from the INTREPID trial, including baseline characteristics, treatment effects (forced expiratory volume in 1 second and St. George's Respiratory Questionnaire score [derived from exploratory COPD assessment test score mapping]), and discontinuation rates, along with German healthcare resource and drug costs (2023 Euros), were used to populate the GALAXY COPD model. The analysis was conducted over a lifetime horizon, with outcomes including life years (LYs), quality-adjusted LYs (QALYs), and incremental cost-utility ratios. The robustness of the analysis was assessed using scenario, one-way sensitivity, and probabilistic analyses.

Results

Improved lifetime outcomes were predicted for FF/UMEC/VI versus non-ELLIPTA MITT, providing additional LYs of 0.174 (95% range: 0.065, 0.322) and QALYs of 0.261 (0.186, 0.346) per patient, together with cost savings of €2,850 (€3,517, €2,220). Additionally, patients receiving FF/UMEC/VI were predicted to experience a reduction in exacerbations (-0.063), highlighting its dominance as the preferred treatment option. These findings remained consistent across one-way sensitivity, scenario, and probabilistic analyses, highlighting the robustness of FF/UMEC/VI as a cost-effective solution for COPD management in Germany.

Conclusion

FF/UMEC/VI offers clinical benefits and cost savings compared with non-ELLIPTA MITT, suggesting that it may reduce the burden of COPD in Germany and warranting consideration as a preferred treatment option by physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveChlorobenzenesBronchodilator AgentsBenzyl AlcoholsQuinuclidinesDrug CostsNebulizers and VaporizersLungMuscarinic AntagonistsAndrostadienesAdrenergic beta-2 Receptor AgonistsHumansCost-Benefit AnalysisGermanyTreatment OutcomeAdministration, InhalationMaleFemaleAgedModels, EconomicMiddle AgedQuality-Adjusted Life YearsDrug CombinationsTime FactorsForced Expiratory VolumeRecovery of FunctionCost Savings

Stichwörter der Autor:innen

Germanychronic obstructive pulmonary diseasecost-effectivenessfluticasone furoate/umeclidinium/vilanterolmultiple-inhaler triple therapysingle-inhaler triple therapy

Substanzen

ChlorobenzenesvilanterolBronchodilator AgentsBenzyl AlcoholsQuinuclidinesfluticasone furoateGSK573719Drug CombinationsMuscarinic AntagonistsAndrostadienes

Autor:innen und Institutionen

  • Insaf Respiratory Research Institute, Taunusstein, Germany.
  • Global Medical Affairs, GSK, Munich, Germany.
  • Insights, Evidence and Value - Health Economics & Epidemiology, ICON Plc, NJ, USA.
  • Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
  • ICON Health Economics, ICON Plc, Vancouver, Canada.
  • Insights, Evidence and Value - Health Economics & Epidemiology, ICON Plc, Houston, TX, USA.

ORCID-Profile: Kai-Michael Beeh, Jing Claussen, Alan Martin, Robyn Kendall, Afisi S Ismaila

Förderung

  • GSK

Zitieren

APA

Beeh, K. M., Claussen, J., Shah, D., Martin, A., Kendall, R., Dasari, P., Ismaila, A. S., & Noorduyn, S. G. (2025). Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s492524

Vancouver

Beeh KM, Claussen J, Shah D, Martin A, Kendall R, Dasari P, et al. Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s492524

BibTeX
@article{Beeh2025,
  author = {Beeh, Kai-Michael and Claussen, Jing and Shah, Dhvani and Martin, Alan and Kendall, Robyn and Dasari, Priyadarsini and Ismaila, Afisi S and Noorduyn, Stephen G},
  title = {Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s492524}
}
Kostenlos starten →